California Medicaid spending on GLP-1 drugs
How much did California Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?
Pharmacies were reimbursed at least $3.46 billion for GLP-1 drugs paid through California Medicaid in 2025, across at least 3,090,452 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 50 rows of 319, so these figures are floors.
Pharmacies were reimbursed at least $537.7 million for GLP-1 drugs paid through California Medicaid in 2026 (quarter 1 only, as posted so far), across at least 498,619 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 16 rows of 86, so these figures are floors.
By year and ingredient
| 2020 | at least $54,589,020 | No data | $38,337,979 | at least $77,900,795 | at least $20,395,327 | $319,279 | $1,258,475 | $660,709 | at least $193,461,582 |
| 2021 | at least $102,170,482 | No data | $40,178,351 | at least $143,919,369 | at least $13,566,430 | $869,840 | $1,722,060 | $519,605 | at least $302,946,136 |
| 2022 | at least $270,073,314 | at least $6,370,537 | at least $69,114,221 | at least $224,469,699 | at least $9,171,144 | at least $263,680 | at least $1,990,662 | at least $739,304 | at least $582,192,561 |
| 2023 | at least $867,000,433 | at least $59,286,722 | at least $98,240,395 | at least $281,352,773 | at least $6,431,429 | at least $9,649 | at least $1,764,021 | at least $799,957 | at least $1,314,885,379 |
| 2024 | at least $1,743,503,676 | at least $237,439,352 | at least $36,973,749 | at least $195,689,376 | $3,445,687 | No data | at least $1,300,036 | at least $561,560 | at least $2,218,913,436 |
| 2025 | at least $2,325,087,297 | at least $991,748,713 | at least $19,837,924 | at least $124,091,865 | at least $715,958 | No data | at least $785,527 | at least $276,693 | at least $3,462,543,976 |
| 2026 (Q1) | at least $318,166,487 | $192,263,663 | at least $2,435,862 | at least $24,620,972 | $8,837 | No data | at least $119,418 | at least $66,186 | at least $537,681,425 |
By product, 2025
| Ozempic | at least $888,872,945 | at least 915,084 | 2 of 39 |
| Rybelsus | $123,413,856 | 85,505 | 0 of 24 |
| Wegovy | $1,312,800,496 | 1,000,304 | 0 of 40 |
| Mounjaro | $247,591,112 | 233,535 | 0 of 48 |
| Zepbound | at least $744,157,601 | at least 701,827 | 12 of 46 |
| Liraglutide (generic name listing) | at least $4,137,026 | at least 9,710 | 16 of 41 |
| Saxenda | at least $13,231,788 | at least 10,868 | 4 of 8 |
| Victoza | $2,469,110 | 3,862 | 0 of 8 |
| Trulicity | at least $124,091,865 | at least 127,774 | 4 of 37 |
| Bydureon | at least $680,485 | at least 816 | 1 of 5 |
| Byetta | at least $27,308 | at least 31 | 2 of 4 |
| Exenatide (generic name listing) | at least $8,165 | at least 11 | 2 of 3 |
| Soliqua | at least $785,527 | at least 916 | 3 of 8 |
| Xultophy | at least $276,693 | at least 209 | 4 of 8 |
By quarter, 2025
| Q1 2025 | at least $707,284,214 | at least 633,559 | 10 of 77 |
| Q2 2025 | at least $692,654,946 | at least 617,914 | 17 of 81 |
| Q3 2025 | at least $1,072,848,849 | at least 955,917 | 10 of 79 |
| Q4 2025 | at least $989,755,968 | at least 883,062 | 13 of 82 |
By quarter, 2026 (posted so far)
| Q1 2026 | at least $537,681,425 | at least 498,619 | 16 of 86 |
The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:
“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”
Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”
CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.
Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.
Sources
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
- State Drug Utilization Data 2020 (data.medicaid.gov)
- State Drug Utilization Data 2021 (data.medicaid.gov)
- State Drug Utilization Data 2022 (data.medicaid.gov)
- State Drug Utilization Data 2023 (data.medicaid.gov)
- State Drug Utilization Data 2024 (data.medicaid.gov)
- State Drug Utilization Data 2025 (data.medicaid.gov)
- State Drug Utilization Data 2026 (data.medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.